Regulatory Post-Marketing Surveillance Study for Brolucizumab
Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu ® Injection, Beovu ®Prefilled Syringe)
Sponsor: Novartis Pharmaceuticals
This observational or N/A phase trial investigates Neovascular Age-related Macular Degeneration and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Feb 2025 — Sep 2025 [monthly]
Recruiting
-
Nov 2024 — Feb 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Jul 2023 — Jul 2024 [monthly]
Recruiting
-
Jan 2023 — Jul 2023 [monthly]
Recruiting
-
Jul 2022 — Jan 2023 [monthly]
Recruiting
-
Oct 2021 — Jul 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .